Opaleye Management as of March 31, 2016
Portfolio Holdings for Opaleye Management
Opaleye Management holds 50 positions in its portfolio as reported in the March 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Axogen (AXGN) | 7.2 | $11M | 2.1M | 5.36 | |
| Ariad Pharmaceuticals | 5.0 | $8.0M | 1.3M | 6.39 | |
| Ultragenyx Pharmaceutical (RARE) | 4.4 | $7.0M | 110k | 63.31 | |
| Fibrogen (FGEN) | 4.4 | $6.9M | 325k | 21.29 | |
| Protalix Biotherapeutics Inc note 4.500% 9/1 | 4.3 | $6.9M | 8.2M | 0.84 | |
| Medgenics | 4.3 | $6.9M | 1.6M | 4.40 | |
| Adamas Pharmaceuticals | 3.8 | $6.1M | 320k | 18.95 | |
| Cara Therapeutics (CARA) | 3.4 | $5.3M | 855k | 6.22 | |
| Sage Therapeutics (SAGE) | 3.3 | $5.3M | 165k | 32.06 | |
| AMAG Pharmaceuticals | 3.2 | $5.1M | 220k | 23.40 | |
| Imprimis Pharmaceuticals | 3.1 | $5.0M | 1.3M | 3.97 | |
| Inotek Pharmaceuticals Corp conv | 3.0 | $4.8M | 645k | 7.40 | |
| DepoMed | 2.9 | $4.5M | 325k | 13.93 | |
| Agios Pharmaceuticals (AGIO) | 2.7 | $4.3M | 105k | 40.60 | |
| Cytrx | 2.6 | $4.1M | 1.4M | 2.86 | |
| Blueprint Medicines (BPMC) | 2.5 | $4.0M | 220k | 18.05 | |
| Geron Corporation (GERN) | 2.4 | $3.9M | 1.3M | 2.92 | |
| Foamix Pharmaceuticals | 2.4 | $3.8M | 590k | 6.52 | |
| Codexis (CDXS) | 2.3 | $3.7M | 1.2M | 3.11 | |
| Tg Therapeutics (TGTX) | 2.2 | $3.5M | 415k | 8.52 | |
| Chimerix (CMRX) | 2.2 | $3.4M | 675k | 5.11 | |
| Ophthotech | 2.1 | $3.4M | 80k | 42.28 | |
| Immunomedics | 2.1 | $3.3M | 1.3M | 2.50 | |
| Xenon Pharmaceuticals (XENE) | 1.8 | $2.8M | 400k | 6.99 | |
| Amarin Corporation (AMRN) | 1.7 | $2.7M | 1.8M | 1.53 | |
| Intec Pharma | 1.7 | $2.6M | 638k | 4.12 | |
| Nabriva Therapeutics | 1.6 | $2.5M | 274k | 8.96 | |
| Eagle Pharmaceuticals (EGRX) | 1.5 | $2.4M | 60k | 40.50 | |
| Affimed Therapeutics B V | 1.4 | $2.3M | 610k | 3.74 | |
| Zogenix | 1.4 | $2.2M | 240k | 9.24 | |
| Retrophin | 1.3 | $2.0M | 150k | 13.66 | |
| Supernus Pharmaceuticals (SUPN) | 1.2 | $1.9M | 125k | 15.25 | |
| Trillium Therapeutics, Inc. Cmn | 1.1 | $1.8M | 195k | 9.25 | |
| Edge Therapeutics | 1.1 | $1.7M | 185k | 9.15 | |
| Cynapsus Therapeutics | 0.9 | $1.4M | 121k | 11.90 | |
| Adaptimmune Therapeutics (ADAP) | 0.9 | $1.4M | 175k | 8.13 | |
| Corium Intl | 0.9 | $1.4M | 360k | 3.86 | |
| Auris Med Hldg | 0.8 | $1.2M | 340k | 3.64 | |
| Ohr Pharmaceutical | 0.7 | $1.2M | 366k | 3.21 | |
| XOMA CORP Common equity shares | 0.7 | $1.0M | 1.4M | 0.77 | |
| Tenax Therapeutics | 0.7 | $1.0M | 500k | 2.05 | |
| Achaogen | 0.4 | $704k | 255k | 2.76 | |
| Nektar Therapeutics (NKTR) | 0.4 | $688k | 50k | 13.76 | |
| Medivation | 0.4 | $667k | 15k | 46.00 | |
| Evoke Pharma | 0.4 | $662k | 130k | 5.09 | |
| Neuroderm Ltd F | 0.3 | $544k | 39k | 14.13 | |
| Nivalis Therapeutics | 0.3 | $417k | 100k | 4.17 | |
| Aclaris Therapeutics (ACRS) | 0.2 | $341k | 18k | 18.94 | |
| Biolinerx Ltd-spons | 0.2 | $255k | 250k | 1.02 | |
| Chiasma | 0.1 | $183k | 20k | 9.15 |
